Noxopharm Limited (NOXOF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 7 Million AUD | -57.42% |
| 2023 | 16.44 Million AUD | 10.0% |
| 2022 | 14.94 Million AUD | 4.17% |
| 2021 | 14.34 Million AUD | -11.02% |
| 2020 | 16.12 Million AUD | 3.34% |
| 2019 | 15.6 Million AUD | 49.44% |
| 2018 | 10.44 Million AUD | 226.5% |
| 2017 | 3.19 Million AUD | 357.05% |
| 2016 | 699.72 Thousand AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 1.76 Million AUD | -49.13% |
| 2024 FY | 7 Million AUD | -57.42% |
| 2024 Q1 | 1.11 Million AUD | -85.3% |
| 2024 Q2 | 3.46 Million AUD | 209.9% |
| 2024 Q4 | 1.76 Million AUD | 0.0% |
| 2023 FY | 16.44 Million AUD | 10.0% |
| 2023 Q3 | 3.71 Million AUD | -57.9% |
| 2023 Q4 | 7.61 Million AUD | 105.07% |
| 2023 Q2 | 8.82 Million AUD | 481.54% |
| 2023 Q1 | 1.51 Million AUD | -82.25% |
| 2022 Q2 | 6.4 Million AUD | 74.68% |
| 2022 Q4 | 8.54 Million AUD | 90.76% |
| 2022 FY | 14.94 Million AUD | 4.17% |
| 2022 Q1 | 3.66 Million AUD | -55.95% |
| 2022 Q3 | 4.47 Million AUD | -30.04% |
| 2021 Q2 | 7.32 Million AUD | 250.79% |
| 2021 FY | 14.34 Million AUD | -11.02% |
| 2021 Q3 | 1.92 Million AUD | -73.78% |
| 2021 Q4 | 8.32 Million AUD | 333.01% |
| 2021 Q1 | 2.08 Million AUD | -67.83% |
| 2020 Q4 | 6.49 Million AUD | 61.12% |
| 2020 FY | 16.12 Million AUD | 3.34% |
| 2020 Q2 | 9.63 Million AUD | 209.98% |
| 2020 Q1 | 3.1 Million AUD | -61.85% |
| 2020 Q3 | 4.03 Million AUD | -58.16% |
| 2019 Q1 | 3.75 Million AUD | 17.06% |
| 2019 Q4 | 8.14 Million AUD | 95.53% |
| 2019 Q3 | 4.16 Million AUD | 10.88% |
| 2019 Q2 | 3.75 Million AUD | -0.0% |
| 2019 FY | 15.6 Million AUD | 49.44% |
| 2018 Q4 | 3.2 Million AUD | 0.0% |
| 2018 FY | 10.44 Million AUD | 226.5% |
| 2018 Q1 | 6.44 Million AUD | 521.71% |
| 2018 Q2 | 6.44 Million AUD | -0.0% |
| 2018 Q3 | 3.2 Million AUD | -50.18% |
| 2017 FY | 3.19 Million AUD | 357.05% |
| 2017 Q1 | 583.83 Thousand AUD | -3.2% |
| 2017 Q4 | 1.03 Million AUD | 0.0% |
| 2017 Q2 | 583.83 Thousand AUD | -0.0% |
| 2017 Q3 | 1.03 Million AUD | 77.45% |
| 2016 FY | 699.72 Thousand AUD | 0.0% |
| 2016 Q2 | 96.26 Thousand AUD | 0.0% |
| 2016 Q4 | 603.11 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 10.86 Million USD | 35.583% |
| Skye Bioscience, Inc. | 13.54 Million USD | 48.329% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 81.21% |
| Nascent Biotech, Inc. | 2.22 Million USD | -213.927% |
| Qrons Inc. | 643.67 Thousand USD | -987.532% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 69.531% |
| CSL Limited | 3.44 Billion USD | 99.797% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 76.313% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -38.836% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -657.998% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 87.813% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1584.848% |
| Rebus Holdings, Inc. | 664 Thousand USD | -954.246% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -424.19% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1696.92% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 56.277% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 91.934% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -42.341% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -2574.626% |
| SQZ Biotechnologies Company | 85.61 Million USD | 91.824% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -140.042% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -366.089% |
| Mesoblast Limited | 5.9 Million USD | -18.607% |
| Marizyme, Inc. | 19.23 Million USD | 63.616% |
| Genus plc | 147.7 Million USD | 95.261% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 20.264% |
| Pharming Group N.V. | 225.49 Million USD | 96.896% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -241.689% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -421.801% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 16.055% |
| ContraFect Corporation | 56.88 Million USD | 87.695% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -58.782% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -373.385% |
| IMV Inc. | 37.7 Million USD | 81.436% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -150.871% |
| MultiCell Technologies, Inc. | 567.42 USD | -1233587.745% |
| ONE Bio Corp. | 6.44 Million USD | -8.633% |
| Accustem Sciences Inc. | 3.74 Million USD | -86.85% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 91.855% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1215.919% |
| Q BioMed Inc. | 3.43 Million USD | -103.694% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 71.676% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -166.418% |
| Biomind Labs Inc. | 994.18 Thousand USD | -604.116% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 92.953% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -297.811% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -4.2% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -275.472% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 28100.764% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -281.462% |
| GB Sciences, Inc. | 1.42 Million USD | -392.795% |
| Alpha Cognition Inc. | 9.7 Million USD | 27.875% |
| HST Global, Inc. | 140.9 Thousand USD | -4867.951% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -522.289% |
| Halberd Corporation | 74.84 Thousand USD | -9253.292% |
| Enzolytics Inc. | 2.17 Million USD | -221.182% |
| Agentix Corp. | 1.37 Million USD | -410.309% |
| Resverlogix Corp. | 12.71 Million USD | 44.932% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -91.749% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.544% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -570.516% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -191.076% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -343.231% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -105.587% |
| AVAX Technologies, Inc. | 7.31 Million USD | 4.242% |
| Zenith Capital Corp. | 8.94 Million USD | 21.724% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.152% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -40082.487% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -185.103% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -3981.53% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -264.421% |
| Kadimastem Ltd | 2.41 Million USD | -190.451% |
| Helix BioMedix, Inc. | 1.97 Million USD | -254.973% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -3757.173% |
| LadRx Corporation | 3.81 Million USD | -83.646% |
| Cell Source, Inc. | 4.32 Million USD | -61.841% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -657.998% |
| NovAccess Global Inc. | 2.46 Million USD | -183.781% |
| Affymax, Inc. | 39.38 Million USD | 82.227% |
| Itoco Inc. | 919.14 Thousand USD | -661.6% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -65.161% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -525.576% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1162.328% |
| CytoDyn Inc. | 18.05 Million USD | 61.235% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -27712.75% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -3080.777% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -393.043% |
| SYBLEU INC | 160.87 Thousand USD | -4251.296% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -285.405% |
| International Stem Cell Corporation | 5.27 Million USD | -32.806% |
| Bioxytran, Inc. | 3.82 Million USD | -83.244% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -13197.73% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -34310.81% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 80.698% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -332.645% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -851.326% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -125.014% |
| Neutra Corp. | 243.82 Thousand USD | -2771.037% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 59.9% |
| PureTech Health plc | 144.59 Million USD | 95.159% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 65.836% |
| IXICO plc | 4.7 Million USD | -48.719% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 20.425% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 94.055% |
| CSL Limited | 3.89 Billion USD | 99.82% |
| Cellectis S.A. | 97.32 Million USD | 92.807% |